Vol. 4 No. 6 (2024): June
Reimbursement Reviews

Treosulfan (Trecondyv)

Published June 7, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses treosulfan (Trecondyv); 5 g/vial; IV infusion.
  • Indication: Treosulfan in combination with fludarabine as part of conditioning treatment before allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies and in pediatric patients older than 1 year old with acute myeloid leukemia or myelodysplastic syndromes.